About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Advec Inc. v. Vector Biosystems Inc.
1:13-cv-00217; filed November 1, 2013 in the Northern District of Florida
Infringement of U.S. Patent No. 6,120,764 ("Adenovirus for Control of Gene Expression," issued September 19, 2000) based on Vector Biosystem's manufacture and sale of its Ad-FLPe and Ad-CMV-Cr products. View the complaint here.
Purdue Pharma L.P. et al. v. Sandoz, Inc.
1:13-cv-07776; filed November 1, 2013 in the Southern District of New York
• Plaintiffs: Purdue Pharma L.P.; P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Grunenthal GmbH
• Defendant: Sandoz, Inc.
Infringement of U.S. Patent Nos. 8,337,888 ("Pharmaceutical Formulation Containing Gelling Agent," issued December 25, 2012) and 8,309,060 ("Abuse-Proofed Dosage Form," issued November 13, 2012) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.
Otsuka Pharmaceutical Co., Ltd. v. Wockhardt Ltd. et al.
3:13-cv-06604; filed October 31, 2013 in the District Court of New Jersey
• Plaintiff: Otsuka Pharmaceutical Co., Ltd.
• Defendants: Wockhardt Ltd.; Wockhardt USA LLC; Wockhardt Bio AG
Infringement of U.S. Patent No. 6,977,257 ("Aripiprazole Oral Solution," issued December 20, 2005) following a Paragraph IV certification as part of Wockhardt's filing of an ANDA to manufacture a generic version of Otsuka's Abilify® (aripiprazole, used to treat bipolar disorder and schizophrenia). View the complaint here.
